Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13958894 | 0.83 | CYSLTR1 (0.49) | PDE10ACYP1A2CYSLTR2CYSLTR1NCF1 | |
| SCHEMBL9688391 | 0.81 | PDE10A (0.50) | PDE10ACYP1A2CYSLTR2CYSLTR1NCF1 | |
| SCHEMBL2913941 | 0.78 | PDE10A (0.61) | PDE10ACYP1A2CYSLTR2CYSLTR1NCF1 | |
| SCHEMBL3107823 | 0.77 | PDE10A (0.50) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL14352218 | 0.77 | PDE10A (0.46) | PDE10ACYP1A2CYSLTR2CYSLTR1CYP3A4 | |
| SCHEMBL22864139 | 0.77 | PDE10A (0.47) | PDE10ACYSLTR2CYSLTR1 | |
| SCHEMBL29858122 | 0.75 | HTT (0.55) | CYP1A2 | |
| SCHEMBL19385987 | 0.75 | HTT (0.55) | CYP1A2 | |
| SCHEMBL22864061 | 0.75 | FAAH (0.39) | PDE10ACYP2D6 | |
| SCHEMBL22864062 | 0.75 | PDE10A (0.43) | PDE10ACYSLTR2CYSLTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137506-A1 | COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS | CURASEN THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| WO-2023225021-A1 | COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) | CURASEN THERAPEUTICS, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| WO-2021003161-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2021-01-07 | — | — | WO | disclosed |
| WO-2020198466-A9 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| WO-2020198466-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. (US) | 2020-10-01 | — | — | WO | disclosed |